scholarly journals Metal-Based Complexes as Pharmaceuticals for Molecular Imaging of the Liver

2019 ◽  
Vol 12 (3) ◽  
pp. 137 ◽  
Author(s):  
Julia Greiser ◽  
Wolfgang Weigand ◽  
Martin Freesmeyer
Keyword(s):  
Magnetic Resonance Imaging ◽  
Positron Emission Tomography ◽  
Metal Complexes ◽  
Imaging Technique ◽  
Imaging Modality ◽  
Emission Tomography ◽  
Resonance Imaging ◽  
Positron Emission ◽  
Magnetic Resonance Imaging Mri ◽  
Uptake Mechanisms

This article reviews the use of metal complexes as contrast agents (CA) and radiopharmaceuticals for the anatomical and functional imaging of the liver. The main focus was on two established imaging modalities: magnetic resonance imaging (MRI) and nuclear medicine, the latter including scintigraphy and positron emission tomography (PET). The review provides an overview on approved pharmaceuticals like Gd-based CA and 99mTc-based radiometal complexes, and also on novel agents such as 68Ga-based PET tracers. Metal complexes are presented by their imaging modality, with subsections focusing on their structure and mode of action. Uptake mechanisms, metabolism, and specificity are presented, in context with advantages and limitations of the diagnostic application and taking into account the respective imaging technique.

Arguments against the biomarker-driven diagnosis of AD

2012 ◽  
Vol 25 (2) ◽  
pp. 177-181 ◽  
Author(s):  
Helen F.K. Chiu ◽  
Henry Brodaty
Keyword(s):  
Magnetic Resonance Imaging ◽  
Positron Emission Tomography ◽  
Cerebrospinal Fluid ◽  
Magnetic Resonance ◽  
Early Diagnosis ◽  
Research Agenda ◽  
Emission Tomography ◽  
Resonance Imaging ◽  
Positron Emission ◽  
Magnetic Resonance Imaging Mri

Impressive developments in the biomarker diagnosis of Alzheimer's disease (AD and pre-symptomatic states, using cerebrospinal fluid (CSF), positron emission tomography (PET), magnetic resonance imaging (MRI), and proteomics, have been at the forefront of research in the last decade. With the publication of the criteria of Dubois et al. (2007) and the revised National Institute on Aging and Alzheimer's Association (NIA–AA) criteria for the diagnosis of AD (Jack et al., 2011), this has further ignited the interest and enthusiasm for researchers and clinicians in the field. In some of the major conferences on dementia in recent years, the topic of the biomarker-driven diagnosis of AD has dominated the research agenda. But many questions arise as to how this research will translate into practice. Here, we would like to put forward our arguments against a biomarker-driven diagnosis of AD, and we would caution that very early diagnosis of AD may not result in better care of the subjects.

Sign in / Sign up

Export Citation Format

Share Document